Metformin: Surprising New Benefits of a Common Diabetes Drug

A widely used diabetes medication may offer unexpected protection for brain health, according to new research that reveals metformin’s potential to reduce neurodegenerative changes after six decades of clinical use.

The findings, published in a recent study, indicate that long-term metformin use is associated with lower markers of brain inflammation and reduced accumulation of abnormal proteins linked to Alzheimer’s disease. Researchers observed these effects in both animal models and human tissue samples, suggesting the drug may influence neurological pathways beyond its primary role in regulating blood glucose.

Metformin, first approved for type 2 diabetes in the 1950s and still among the most prescribed medications worldwide, has long been studied for its off-target effects. Previous investigations have linked it to reduced cancer risk, improved cardiovascular outcomes, and extended lifespan in model organisms. This latest work shifts focus to the central nervous system, where chronic inflammation and protein misfolding are hallmarks of age-related cognitive decline.

In laboratory experiments, mice treated with metformin showed decreased activation of microglia — immune cells in the brain that, when overactive, contribute to neuroinflammation. Similarly, analysis of post-mortem human brain tissue revealed that individuals with a history of metformin use had lower levels of phosphorylated tau and amyloid-beta aggregates, two key biomarkers of Alzheimer’s pathology.

“We’re seeing consistent signals that metformin may modulate brain immune responses and reduce pathological hallmarks of dementia,” said a lead researcher involved in the study. “While we cannot yet conclude that metformin prevents Alzheimer’s disease in humans, the biological plausibility is strong, and the safety profile of the drug makes it a compelling candidate for further investigation.”

The study did not involve clinical trials testing metformin as a treatment for cognitive decline, and experts caution against drawing direct therapeutic conclusions from observational and preclinical data. Confounding factors — such as healthier lifestyle choices among metformin users or differences in access to care — could influence the observed associations.

Still, the consistency of findings across models has prompted interest in repurposing metformin for neuroprotection. Several observational studies in human populations have reported lower incidence of dementia among diabetic patients taking metformin compared to those on other glucose-lowering therapies, though randomized controlled trials are needed to confirm causality.

Researchers emphasize that metformin is not a substitute for established brain-healthy behaviors such as regular physical activity, cognitive engagement, and vascular risk management. However, its low cost, widespread availability, and decades-long safety record make it a practical subject for future prevention-focused trials.

Ongoing studies are now examining whether metformin can slow cognitive decline in non-diabetic older adults at risk for Alzheimer’s disease. Results from these trials, expected in the coming years, will help determine whether this long-standing diabetes drug has a role to play in preserving brain function with age.